Celltrion Juggles Biosimilar Market Share As It Shifts To Direct Marketing
Korean Firm Also Settles Avastin Litigation To Allow CT-P16 Bevacizumab Launch
Executive Summary
Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.
You may also be interested in...
Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
Settlement Gives Celltrion Date For US Higher-Strength Humira Biosimilar
Celltrion has secured a US launch date for its higher-strength adalimumab biosimilar, Yuflyma, through a settlement with AbbVie. However, the company will face a number of other Humira rivals in 2023.
Celltrion Reveals Data As It Rolls Out Higher-Strength Adalimumab
As it begins to roll out its Yuflyma higher-strength adalimumab biosimilar in Europe, Celltrion has reported positive one-year data from a Phase III trial for the 100mg/ml Humira rival.